Bromazepam
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Bromazepam: From Its Marketed Benzodiazepine Use to Migraine Disorder
One-Sentence Summary
Bromazepam is a benzodiazepine marketed in Canada as several generic products. The Canadian license data compiled for this report does not list an approved indication text. The TxGNN model predicts it may be effective for migraine disorder, but no clinical trials and no publications currently support this direction, so the prediction rests on the computational model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the compiled license data |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9906 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 4 of 4) |
| Number of DINs | 4 (marketed: 4) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on its drug class, bromazepam is a benzodiazepine that acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
A possible link to migraine is that GABAergic inhibition may dampen cortical spreading depression and trigeminovascular hyperexcitability. Its anxiolytic and muscle-relaxant effects could also reduce stress-related triggers and the tension component of headache.
This link is inferred from drug-class properties, not from bromazepam-specific data. The high TxGNN score is a computational prediction only. Benzodiazepines are not established migraine therapies. Dependence, tolerance, sedation and concerns about medication-overuse headache argue against use in a chronic, recurrent condition like migraine.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02230584 | TEVA-BROMAZEPAM | Not listed | Not listed |
| 02230585 | TEVA-BROMAZEPAM | Not listed | Not listed |
| 02177161 | APO-BROMAZEPAM | Not listed | Not listed |
| 02177188 | APO-BROMAZEPAM | Not listed | Not listed |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN score, with no registered trials or publications (Evidence Level L5). The mechanistic rationale is generic to the drug class, and the known risks of benzodiazepines (dependence, tolerance, sedation, medication-overuse headache concerns) are a poor fit for a chronic, recurrent condition like migraine.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications, which are required before any safety screening
- Bromazepam-specific mechanism of action data
- Approved indication text and dosage forms for the Canadian licenses
- Preclinical or clinical evidence linking bromazepam or related benzodiazepines to migraine
- A risk-benefit assessment of dependence and medication-overuse headache for a chronic migraine population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.